arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Actinium Pharmaceuticals, Inc.

ATNM Health Care Biotechnology: Pharmaceutical Preparations
$1.03
▼ -0.5% Today
as of Sep 4, 16:46 ET
Last 30 days +18.80% Jul 28 → Sep 04
$0.72 $0.83 $0.94 $1.05 $1.16 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$1.05
High
$1.05
Low
$1.02
Volume
$53,954
Avg Vol
$163,911
Mkt Cap
$35M
P/E (TTM)
1.87
Beta
—
52w High
$1.74
52w Low
$0.73
Div Yield
—
Shares Out
$31M

Recent Press Releases & News last 60 days · 3 items

Sep 4 · 21:05 PR PR Newswire
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 14 · 21:02 PR PR Newswire
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
Aug 7 · 21:07 Associated Press
Actinium: Q2 Earnings Snapshot

Overview

52-week range
$0.73
$1.74
29% of range
Avg surprise (last 3)
-15.6%
Avg reaction (last 2)
+5.4%
100% positive
Latest IV / EM
1833%
EM ±286.4% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.58$-0.21$0.16$0.52$0.89 Actual $-0.43Actual $-0.58Actual $-0.49Actual $-0.31Actual $-0.38Actual $-0.37Actual $-0.51Est $-0.26Actual $-0.22Est $-0.32Actual $-0.16Actual $-0.18Est $-0.22Actual $0.89 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-16M$-3M$10M$24M$37M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $0.89 — — — — financials
Fri May 8, 2026Mar/2026 $-0.18 $-0.22 +18.2% +64.7% +7.4% earnings
Tue Sep 30, 2025Sep 2025 $-0.16 — — — — financials
Fri Aug 8, 2025Jun/2025 $-0.22 $-0.32 +31.2% — — earnings
Fri May 9, 2025Mar/2025 $-0.51 $-0.26 -96.2% — +3.5% earnings
Mon Sep 30, 2024Sep 2024 $-0.37 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.38 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.31 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.49 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.58 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.43 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$35M——$90,000————
Cost of revenue————————
Gross profit————————
Operating income$28M$-6M—$-6M$-8M$-17M—$-13M
Net income$28M$-6M—$-5M$-7M$-16M—$-12M
EPS (diluted)$0.89$-0.18—$-0.16$-0.22$-0.51—$-0.37

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$36M$42M$48M$53M$60M$65M$73M$79M
Inventory————————
Total current assets$38M$43M$49M$54M$61M$66M$75M$80M
Total assets$40M$45M$52M$56M$63M$69M$77M$82M
Long-term debt————————
Total liabilities$10M$43M$44M$42M$44M$43M$44M$44M
Total equity$30M$2M$8M$14M$19M$26M$33M$38M

Implied volatility — last 90 days

768%2728%4689%6649%8609% Jun 07 — IV 1905% · EM ±263.9%Jun 08 — IV 2000% · EM ±264.2%Jun 09 — IV 2292% · EM ±287.1%Jun 10 — IV 2419% · EM ±285.7%Jun 11 — IV 2567% · EM ±283.7%Jun 12 — IV 2807% · EM ±287.1%Jun 15 — IV 4078% · EM ±295.0%Jun 16 — IV 5097% · EM ±301.0%Jun 17 — IV 6808% · EM ±284.3%Jun 19 — IV 769% · EM ±169.9%Jun 22 — IV 1372% · EM ±286.4%Jun 23 — IV 1438% · EM ±294.1%Jun 24 — IV 1458% · EM ±292.1%Jun 25 — IV 1827% · EM ±357.9%Jun 26 — IV 1610% · EM ±308.1%Jun 29 — IV 1739% · EM ±308.1%Jun 30 — IV 1807% · EM ±311.2%Jul 01 — IV 1863% · EM ±311.3%Jul 02 — IV 1922% · EM ±310.9%Jul 03 — IV 1990% · EM ±310.9%Jul 06 — IV 2254% · EM ±312.2%Jul 07 — IV 2236% · EM ±295.2%Jul 08 — IV 2427% · EM ±304.1%Jul 09 — IV 2618% · EM ±309.3%Jul 10 — IV 2919% · EM ±322.6%Jul 13 — IV 4101% · EM ±342.5%Jul 14 — IV 4942% · EM ±357.5%Jul 15 — IV 5798% · EM ±342.4%Jul 16 — IV 8609% · EM ±359.6%Jul 20 — IV 1510% · EM ±356.7%Jul 21 — IV 1529% · EM ±355.6%Jul 22 — IV 1894% · EM ±433.3%Jul 23 — IV 1946% · EM ±437.7%Jul 24 — IV 2078% · EM ±459.3%Jul 27 — IV 2242% · EM ±468.2%Jul 28 — IV 2228% · EM ±455.9%Jul 29 — IV 2386% · EM ±478.0%Jul 30 — IV 2440% · EM ±477.9%Jul 31 — IV 2497% · EM ±478.0%Aug 03 — IV 2817% · EM ±499.1%Aug 04 — IV 2904% · EM ±500.0%Aug 05 — IV 2758% · EM ±460.8%Aug 06 — IV 3209% · EM ±519.1%Aug 07 — IV 3290% · EM ±514.2%Aug 10 — IV 3187% · EM ±441.4%Aug 11 — IV 3294% · EM ±435.0%Aug 12 — IV 3256% · EM ±408.0%Aug 13 — IV 2854% · EM ±337.2%Aug 14 — IV 2741% · EM ±302.9%Aug 17 — IV 3250% · EM ±271.4%Aug 18 — IV 3818% · EM ±276.2%Aug 19 — IV 4195% · EM ±247.8%Aug 20 — IV 5986% · EM ±250.0%Aug 24 — IV 1300% · EM ±271.4%Aug 25 — IV 1290% · EM ±263.9%Aug 26 — IV 1409% · EM ±282.2%Aug 27 — IV 1557% · EM ±305.0%Aug 28 — IV 1526% · EM ±292.1%Aug 31 — IV 1632% · EM ±289.2%Sep 01 — IV 1779% · EM ±306.4%Sep 02 — IV 1766% · EM ±295.0%Sep 03 — IV 1737% · EM ±281.0%Sep 04 — IV 1833% · EM ±286.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in